MGC Pharmaceuticals Limited Date of AGM & Closing Date of Director Nominations (4198P)

TIDMMXC

RNS Number : 4198P

MGC Pharmaceuticals Limited

09 October 2023

MGC Pharmaceuticals Ltd.

Date of AGM and Closing Date for Director Nominations

9 October 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) advises that in accordance with ASX Listing Rule 3.13.1, the Company's Annual General Meeting is planned to be held on Thursday, 30 November 2023.

The closing date for receipt of nominations for persons wishing to be considered for election as a director is, 31 October 2023. Any nominations must be received at the Company's registered office no later than 5:00pm (AWST) on 24 October 2023.

-Ends-

Authorised for release by the Managing Director, for further information please contact:

 
 MGC Pharmaceuticals Ltd            MGC Pharmaceuticals Ltd 
  Roby Zomer                         Rowan Harland 
  CEO & Managing Director            Company Secretary 
  +61 8 6555 2950                    +61 8 6555 2950 
  info@mgcpharma.co.uk               info@mgcpharma.co.uk 
 UK IR/PR Advisers                  UK Brokers 
  IFC Advisory                       Oberon Capital 
  Graham Herring / Tim Metcalfe /    Aimee McCusker / Adam Pollock 
  Zach Cohen                         +44 203 179 5300 
  +44 203 934 6630                   aimeemccusker@oberoninvestments.com 
  mgcpharma@investor-focus.co.uk     adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAMLBLTMTMMMMJ

(END) Dow Jones Newswires

October 09, 2023 05:03 ET (09:03 GMT)

Mgc Pharmaceuticals (LSE:MXC)
過去株価チャート
から 2 2025 まで 3 2025